{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:52:06Z","timestamp":1791917526833,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101342","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:45:48Z","timestamp":1761788748000},"page":"101342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies"],"prefix":"10.1016","volume":"74","author":[{"given":"Xiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.blre.2025.101342_bb0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1532\/IJH97.04197","article-title":"Bone marrow transplantation from the personal viewpoint","volume":"81","author":"Thomas","year":"2005","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101342_bb0010","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2025.101342_bb0015","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","article-title":"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101342_bb0020","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101342_bb0025","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.blre.2025.101342_bb0030","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.blre.2025.101342_bb0035","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2025.101342_bb0040","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"issue":"5891","key":"10.1016\/j.blre.2025.101342_bb0045","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.blre.2025.101342_bb0050","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.blre.2025.101342_bb0055","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.blre.2025.101342_bb0060","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.blre.2025.101342_bb0065","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101342_bb0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101342_bb0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101342_bb0080","article-title":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma","author":"Research C for DE","year":"2024","journal-title":"FDA"},{"key":"10.1016\/j.blre.2025.101342_bb0085","article-title":"FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma","author":"Research C for DE","year":"2023","journal-title":"FDA"},{"key":"10.1016\/j.blre.2025.101342_bb0090","article-title":"FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma","author":"Research C for DE","year":"2025","journal-title":"FDA"},{"key":"10.1016\/j.blre.2025.101342_bb0095","article-title":"FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma","author":"Research C for DE","year":"2024","journal-title":"FDA"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101342_bb0100","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2024.42.16_suppl.7531","article-title":"Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Rodriguez Valdes","year":"2024","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101342_bb0105","doi-asserted-by":"crossref","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"JCO"},{"issue":"10301","key":"10.1016\/j.blre.2025.101342_bb0110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u00d7CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.blre.2025.101342_bb0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.blre.2025.101342_bb0120","article-title":"P879: Long-term Follow-up from Majestec-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"7","author":"Sidana","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.blre.2025.101342_bb0125","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.blre.2025.101342_bb0130","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101342_bb0135","article-title":"Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives","author":"Waldschmidt","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.blre.2025.101342_bb0140","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"24","key":"10.1016\/j.blre.2025.101342_bb0145","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101342_bb0150","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2025.43.16_suppl.7528","article-title":"Efficacy and safety from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: analyses at an extended median follow-up","volume":"43","author":"Rasche","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.blre.2025.101342_bb0155","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(23)01572-0","article-title":"OA-05 efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses","volume":"23","author":"Harrison","year":"2023","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"10.1016\/j.blre.2025.101342_bb0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101342_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000515","article-title":"Cytokine release syndrome biology and management","volume":"27","author":"Cobb","year":"2021","journal-title":"Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101342_bb0170","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1182\/blood-2024-207295","article-title":"Optec: a phase 2 study to evaluate outpatient step-up Administration of Teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM): updated results","volume":"144","author":"Rifkin","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101342_bb0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.blre.2025.101342_bb0180","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101342_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.blre.2025.101342_bb0190","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.blre.2025.101342_bb0195","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European myeloma network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.blre.2025.101342_bb0200","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101342_bb0205","author":"Richter","year":"2024"},{"issue":"2","key":"10.1016\/j.blre.2025.101342_bb0210","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.2024026622","article-title":"Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101342_bb0215","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.blre.2025.101342_bb0220","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101342_bb0225","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101342_bb0230","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.blre.2025.101342_bb0235","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2023011242","article-title":"Immune status and selection of patients for immunotherapy in myeloma: a proposal","volume":"8","author":"Dhodapkar","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2025.101342_bb0240","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.blre.2025.101342_bb0245","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101342_bb0250","series-title":"Efficacy of anti-BCMA CAR-T cell therapies in multiple myeloma patients with prior exposure to bispecific antibodies- results from a retrospective multi-center registry analysis","author":"Waldschmidt","year":"2024"},{"issue":"11","key":"10.1016\/j.blre.2025.101342_bb0255","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101342_bb0260","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101342_bb0265","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.blre.2025.101342_bb0270","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.blre.2025.101342_bb0275","article-title":"S194: S194: Teclistamab (Tec) + Nirogacestat (Niro) in relapsed\/refractory multiple myeloma (RRMM): the phase 1b Majestec-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.blre.2025.101342_bb0280","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41375-025-02757-6","article-title":"Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma","volume":"39","author":"Neubert","year":"2025","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.blre.2025.101342_bb0285","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2025.101342_bb0290","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101342_bb0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2024-200181","article-title":"Teclistamab, Daratumumab, and Pomalidomide in patients with relapsed\/refractory multiple myeloma: results from the Majestec-2 cohort a and Trimm-2 studies","volume":"144","author":"D\u2019Souza","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101342_bb0300","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2025.43.16_suppl.7513","article-title":"Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial results from the LINKER-MM2 trial","volume":"43","author":"Manier","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.blre.2025.101342_bb0305","article-title":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens","author":"Rieger","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101342_bb0310","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood-2024-210520","article-title":"Efficacy of Elranatamab (ELRA) in combination with carfilzomib (CFZ) and dexamethasone (DEX) in the phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"144","author":"Tomasson","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101342_bb0315","doi-asserted-by":"crossref","first-page":"TPS8074","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: an open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101342_bb0320","doi-asserted-by":"crossref","first-page":"TPS7577","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7577","article-title":"MagnetisMM-30: a phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"42","author":"Lesokhin","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.blre.2025.101342_bb0325","author":"Perrot"},{"issue":"2","key":"10.1016\/j.blre.2025.101342_bb0330","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101342_bb0335","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results","volume":"43","author":"van de Donk","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.blre.2025.101342_bb0340","article-title":"Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: initial results from MagnetisMM-6 part 1","volume":"1","author":"Pour","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101342_bb0345","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1182\/blood-2022-159756","article-title":"MajesTEC-4 (EMN30): a phase 3 trial of Teclistamab + Lenalidomide versus Lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101342_bb0350","series-title":"Phase 2 study of Teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): Results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial","author":"Raab","year":"2024"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101342_bb0355","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2024-203391","article-title":"Classic anti-myeloma treatments Alter circulating immune cell subsets with potential implications for T cell immunotherapies in multiple myeloma","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:26:27Z","timestamp":1773329187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":71,"alternative-id":["S0268960X25000876"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101342","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101342"}}